1/5/1 (Item 1 from file: 351)
DIALOG(R)File 351:Derwent WPI

010265930 **Image available**
WPI Acc No: 1995-167185/**199522**
XRAM Acc No: C95-077405

Aq. suspension liq. for treating cataract and corneal disorders - comprises 5-(3-ethoxy-4-N-pentyl-oxyphenyl)-thiazolidine-2,4- dione fine crystals, aq. macromolecular cpd.,, chloro-butanol and benzalkonium chloride

Patent Assignee: SENJU SEIYAKU KK (SENP); TAKEDA CHEM IND LTD (TAKE)
Number of Countries: 001 Number of Patents: 002
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
JP 7089857	A	19950404	JP 94176420	A	19940728	199522	B
JP 2787131	B2	19980813	JP 94176420	A	19940728	199837	

Priority Applications (No Type Date): JP 93189629 A 19930730
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 7089857	A		5	A61K-031/425	
JP 2787131	B2		4	A61K-031/425	Previous Publ. patent JP 7089857

Abstract (Basic): JP 7089857 A

Aq. suspension liq. of fine crystal of 5-(3-ethoxy-4-n-pentyloxyphenyl)thiazolidine-2,4-dione (CGT-112) comprises (1) aq. macromolecular cpd. (2) chlorobutanol and (3) benzalkonium chloride and/or paraoxybenzoic acid ester.

The dia. of the fine crystals of CT-112 is pref. less than 10 mcirons. Aq. macromolecular cpd. is pref. hydroxypropyl methyl cellulose. Ester of bennzalkonium chloride and/or paraoxy benzoate is pref. paraoxybenzoate ester. The amt. of aq. macromolecular cpd. and CT-112 is pref. 0001-5.0 w/v% and 0.01-5.0 w/v%, respectively. The amt. of benzalkonium chloride and/or paraoxybenzoate ester is 0.0005-0.1 w/v%.

USE/ADVANTAGE - CT-112 is used for the prevention and treatment of cataract, corneal disorder and iridocyclitis caused by diabetes. CT-112 is homogeneously dispersed in the aq. suspension as the size of the particles is less than 10 microns. The liq. is stable over a long period and prevents pain when administered as eye drops.

In an example, NaOH (1.4g), AcONa (2g) were dissolved in purified water (200ml), and CT-112 (10g) was added to the soln., 200 ml soln. contg. HPMC (2g) was added to the soln.. The soln. was sterilised by filtration (pH: 11.7) 0.5 N HCl was added dropwise to the soln. with stirring to adjust the pH at 5.5. Sterilised soln. (2500ml) contg. concn. glycerol (88g), paraoxy methyl benzoate (1g), HPMC (2g), chlorobutanol (12g), sodium edetate (0.8g) and sodium acetate (2g) was added. Then purified water was added to make up 4000 ml soln.

Dwg.0/0

Title Terms: AQUEOUS; SUSPENSION; LIQUID; TREAT; CATARACT; CORNEA; DISORDER ; COMPRISE; ETHOXY; N; PENTYL; THIAZOLIDINE; DI; ONE; FINE; CRYSTAL; AQUEOUS; MACROMOLECULAR; COMPOUND; CHLORO; BUTANOL; BENZALKONIUM; CHLORIDE
Derwent Class: B03; B07
International Patent Class (Main): A61K-031/425
International Patent Class (Additional): A61K-009/107; A61K-047/10; A61K-047/14; C07D-277/34
File Segment: CPI

1/5/2 (Item 1 from file: 347)
DIALOG(R)File 347:JAPIO

04797257
AQUEOUS SUPENSION SOLUTION

PUB. NO.: 07-089857 **JP 7089857** A]
PUBLISHED: April 04, 1995 (19950404)
INVENTOR(s): NAKAYAMA HISAYUKI
USHIO KAZUMICHI
INADA KATSUHIRO
APPLICANT(s): SENJU PHARMACEUT CO LTD [402938] (A Japanese Company or Corporation), JP (Japan)
TAKEDA CHEM IND LTD [000293] (A Japanese Company or Corporation), JP (Japan)
APPL. NO.: 06-176420 [JP 94176420]
FILED: July 28, 1994 (19940728)
INTL CLASS: [6] A61K-031/425; A61K-009/107; C07D-277/34
JAPIO CLASS: 14.4 (ORGANIC CHEMISTRY -- Medicine); 14.1 (ORGANIC CHEMISTRY -- Organic Compounds); 14.2 (ORGANIC CHEMISTRY -- High Polymer Molecular Compounds)
JAPIO KEYWORD: R042 (CHEMISTRY -- Hydrophilic Plastics)

ABSTRACT

PURPOSE: To obtain a stable aqueous suspension solution containing 5-(3-ethoxy-4- n-pentyloxyphenyl) thiazolidine-2,4-dione useful as a therapeutic agent for corneal disorder as an active ingredient.

CONSTITUTION: This aqueous suspension solution of fine crystal of 5-(3-ethoxy-4- n-pentyloxyphenyl)thiazolidine-2,4-dione contains a water-soluble polymer, chlorobutanol and benzalkonium chloride and/or p-oxybenzoic ester.

2/5/1 (Item 1 from file: 351)
DIALOG(R)File 351:Derwent WPI

012380094 **Image available**
WPI Acc No: 1999-186201/**199916**
XRAM Acc No: C99-054724

Use of 3-alkoxy-pyridine derivative with non-peptide angiotensin II acceptor antagonism activity - to prevent or treat intravascular membrane hypertrophy due to e.g. reconstriction after PTCA and arteriosclerosis

Patent Assignee: MEIJI SEIKA KAISHA LTD (MEIJ)
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
JP 11035464	A	19990209	JP 97197630	A	19970723	199916	B

Priority Applications (No Type Date): JP 97197630 A 19970723
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 11035464	A		4	A61K-031/44	

Abstract (Basic): JP 11035464 A

Use of a 3-alkoxypyridine derivative of formula (I) or a salt with non-peptide angiotensin II acceptor antagonism activity for preventing or treating intravascular membrane hypertrophy, is new. A = COOH or tetrazol-5-yl; R1, R2 = H or lower alkyl; R3 = H, lower alkyl (optionally substituted by halo, 3-7C cycloalkyl, 5-6-membered saturated heterocyclic group containing 1 N and optionally substituted by lower alkyl, or H2NCO optionally substituted by lower alkyl), lower alkenyl, 3-7C cycloalkyl or benzyl (optionally ring-substituted by halo, lower alkyl, halo(lower alkyl) or lower alkoxy).

ADVANTAGE - (I) are useful for preventing and treating diseases due to reconstriction after PTCA and arteriosclerosis.

Dwg.0/0

Title Terms: ALKOXY; PYRIDINE; DERIVATIVE; NON; PEPTIDE; ANGIOTENSIN; ACCEPT; ANTAGONIST; ACTIVE; PREVENT; TREAT; INTRAVASCULAR; MEMBRANE; HYPERTROPHY; AFTER; ARTERIOSCLEROSIS
Derwent Class: B03
International Patent Class (Main): A61K-031/44
International Patent Class (Additional): C07D-213/69; C07D-401/12
File Segment: CPI

2/5/2 (Item 1 from file: 347)
DIALOG(R)File 347:JAPIO

06093948 **Image available**
MEDICINE CONTAINING 3-ALKOXYPYRIDINE DERIVATIVE AND USED FOR PREVENTING OR TREATING VASCULAR INTIMAL HYPERPLASIA

PUB. NO.: 11-035464 A]
PUBLISHED: February 09, 1999 (19990209)
INVENTOR(s): HACHISU MITSUGI
YASUDA HISAE
IIDA HIROYUKI
FUJISHIMA KAZUYUKI
KATANO KIYOAKI
APPLICANT(s): MEIJI SEIKA KAISHA LTD
APPL. NO.: 09-197630 [JP 97197630]
FILED: July 23, 1997 (19970723)
INTL CLASS: A61K-031/44; A61K-031/44

ABSTRACT

PROBLEM TO BE SOLVED: To obtain a medicine for preventing or treating

vascular initmal hyperplasia by using a specific 3-alkoxypyridine derivative having a non-peptide angiotensin II receptor-antagonizing action as an active ingredient.

SOLUTION: This medicine contains a 3-alkoxypyridine derivative of the formula (A is carboxyl or tetrazol-5-yl; R1 and R2 are each H or an alkyl; R3 is H, an alkyl, an alkenyl, a cycloalkyl or benzyl) having a non-peptide angiotensin II receptor-antagonizing action or its pharmacologically acceptable non-toxic salt as an active ingredient. The compound of the formula is preferably especially 2,6-dimethyl-3-methoxy-4-[2'-(tetrazol-5-yl)biphenyl-4- yl]methoxypyridine. The compound is preferably added in an amount of 1-70 wt.% to a pharmaceutical composition, and preferably administered at a daily dose of about 0.1-300 mg for an adult.